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Abstract
Background
Prions demonstrate an unusual resistance to methods effective at inactivating conventional microorganisms.
This has resulted in a very tangible and difficult infection control challenge to the medical and veterinary
communities, as well as animal agriculture and related industries. Currently accepted practices of harsh
chemical treatments such as prolonged exposure to sodium hydroxide or sodium hypochlorite, or autoclaving
are not suitable in many situations. Less caustic and more readily applicable treatments to contaminated
environments are therefore desirable. We recently demonstrated that exposure of the RML scrapie agent to a
commercial product containing sodium percarbonate (SPC-P) with or without sodium dodecyl sulfate (SDS)
rendered PrPSc sensitive to proteinase K (PK), but did not eliminate infectivity. The current study was
designed to evaluate the efficacy of a combinatorial approach to inactivating prions by exposing RML-positive
brain homogenate to SPC-P and SDS followed by PK. Treated samples were evaluated for PrPSc-
immunoreactivity by western blot, and residual infectivity by mouse bioassay.
Results
Treatment of infected brain homogenate with SPC-P and SDS followed by PK exposure resulted in a 4–5
log10 reduction in infectivity when bioassayed in tga20 mice.
Conclusions
This study demonstrates that exposure of the RML scrapie agent to SPC-P and SDS followed by PK markedly
reduces, but does not eliminate infectivity. The results of this study encourage further investigation into
whether consecutive or concomitant exposure to sodium percarbonate, SDS, and a protease may serve as a
viable and non-caustic option for prion inactivation.
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Abstract
Background: Prions demonstrate an unusual resistance to methods effective at inactivating conventional
microorganisms. This has resulted in a very tangible and difficult infection control challenge to the medical and
veterinary communities, as well as animal agriculture and related industries. Currently accepted practices of harsh
chemical treatments such as prolonged exposure to sodium hydroxide or sodium hypochlorite, or autoclaving are
not suitable in many situations. Less caustic and more readily applicable treatments to contaminated environments
are therefore desirable. We recently demonstrated that exposure of the RML scrapie agent to a commercial product
containing sodium percarbonate (SPC-P) with or without sodium dodecyl sulfate (SDS) rendered PrPSc sensitive to
proteinase K (PK), but did not eliminate infectivity. The current study was designed to evaluate the efficacy of a
combinatorial approach to inactivating prions by exposing RML-positive brain homogenate to SPC-P and SDS
followed by PK. Treated samples were evaluated for PrPSc-immunoreactivity by western blot, and residual infectivity
by mouse bioassay.
Results: Treatment of infected brain homogenate with SPC-P and SDS followed by PK exposure resulted in a 4–5
log10 reduction in infectivity when bioassayed in tga20 mice.
Conclusions: This study demonstrates that exposure of the RML scrapie agent to SPC-P and SDS followed by PK
markedly reduces, but does not eliminate infectivity. The results of this study encourage further investigation into
whether consecutive or concomitant exposure to sodium percarbonate, SDS, and a protease may serve as a viable
and non-caustic option for prion inactivation.
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Background
Prions are the causative agent of the transmissible
spongiform encephalopathies (TSE) and consist predom-
inantly, if not solely, of an abnormally folded, partially
protease resistant isoform of the cellular prion protein
(termed PrPSc) [1]. However, the exact nature of the infec-
tious agent remains open to debate with the identification
of protease sensitive forms of disease-associated PrP [2-4]
and retention of infectivity after complete PrP digestion
[5]. Regardless of their specific identity, prions are notori-
ously difficult to inactivate, withstanding methods effective
against conventional pathogens, such as moderate heating,
ultraviolet irradiation, and formalin exposure [6]. Prions
are transmitted more efficiently within a species, but inter-
species transmission is also possible – the most infamous
example being transmission of bovine spongiform enceph-
alopathy (BSE) to humans resulting in the variant form of
Creutzfeldt-Jakob disease (vCJD) [7-9]. Because BSE poses
a lethal zoonotic disease risk, effective prion decontamin-
ation methods that can be applied on a large scale, such as
in abattoirs, are desirable to further minimize the risk of
zoonotic transmission. Efficacious decontamination proce-
dures that can be applied to environmental settings are
also desirable to aid in the control of other TSEs of veter-
inary and public health importance such as scrapie and
chronic wasting disease, which are horizontally transmit-
ted [10,11]. Ideally, effective methods would be non-
hazardous to personnel applying them on a large scale
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and reasonably sensitive to ecological systems when ap-
plied to contaminated outdoor environments.
Current decontamination recommendations by the
World Health Organization, depending on material to
be sterilized, include autoclaving at 134°C for up to
1 hour, or prolonged exposure to 1 N sodium hydroxide
or ≥ 20,000 ppm sodium hypochlorite [12]. The most re-
cent edition of the US Department of Health and Human
Service’s Biosafety in Microbiological and Biomedical
Laboratories also recognizes the phenolic disinfectant
Environ LpH (Steris Corp.) as an acceptable decontaminat-
ing solution for surfaces and reusable instruments [13]. In-
activation treatments with sodium hydroxide or sodium
hypochlorite are especially detrimental to delicate surgical
and diagnostic equipment, spurring research into less caus-
tic alternatives. Recent lines of investigation have included
treatment of contaminated material with sodium dodecyl
sulfate (SDS), proteolytic enzymes, or peroxygen com-
pounds with variable success. Sodium dodecyl sulfate has
long been known to affect prion infectivity, but its effect-
iveness varies with the prion strain to which it is applied.
Prior investigations have demonstrated minimal effects on
CJD infectivity [14], but up to a 3 log10 reduction on scra-
pie infectivity [15]. More recently, SDS in combination
with NaOH has been shown to successfully inactivate the
263 K hamster scrapie agent, resulting in a > 5.5 log10 re-
duction in infectivity [16,17]. Proteases have also been
reported to have prion inactivation potential [18-22]. Broad
spectrum proteases, such as proteinase K (PK) [18] and
pronase [19], have been shown to substantially reduce in-
fectivity after prolonged exposure times. More recently, a
genetically engineered variant of subtilisin applied under
alkaline conditions was shown to reduce infectivity of a
mouse-adapted BSE strain by > 7 logs [21]. While these re-
agents have demonstrated anti-prion activity on their own,
combining proteases and SDS appears to enhance their
prion inactivating abilities. In two independent studies,
pronase [19] or pronase and PK [23] in combination with
SDS resulted in greater reductions in infectivity ver-
sus protease(s) alone. Peroxygens, such as liquid
hydrogen peroxide [24-26] and peracetic acid [27],
have been shown to promote limited inactivation.
However, more recent studies have demonstrated sig-
nificant reductions in infectivity for hamster-adapted
scrapie and mouse-adapted BSE strains using vapor-
ized hydrogen peroxide [25,28].
Sodium percarbonate is an oxidizing agent composed
of sodium carbonate and hydrogen peroxide (2 Na2CO3 •
3 H2O2). It has a high degree of environmental compati-
bility, with degradation products consisting of water, oxy-
gen, and sodium carbonate, and generates a pH of 10–11
in aqueous solution. Until recently, its efficacy with regard
to prion inactivation had not been reported. In a prior
study [29], we found that exposure of RML-positive brain
homogenate to a sodium percarbonate-containing product
(SPC-P) with or without SDS was unsuccessful at elimin-
ating infectivity, but did increase sensitivity of PrPSc to PK
digestion. The current study builds upon those results,
examining a combinatorial approach to inactivating prions
by exposing infected material to SPC-P and SDS followed
by treatment with PK. Brain homogenate from terminally
ill C57BL/6 mice positive for the mouse-adapted RML
strain of scrapie was treated with a combination of SPC-P
and 2.5% w/v SDS for 30 minutes at room temperature
followed by exposure to PK. Western blot (WB) analysis
was used to detect residual PrPSc in treated samples, and
residual infectivity was assayed by intracranial inoculation
into prion protein overexpressing tga20 mice [30].
Results
Immunoblotting
Residual PrPSc in brain homogenate treated with a low
or high concentration of the SPC-containing product
(SPC-PL and SPC-PH, respectively) in combination with
2.5% w/v SDS followed by exposure to PK was assayed
via western blot (WB). Immunoblots were performed in
triplicate with representative blots presented in Figure 1.
Immunoreactivity for the di-, mono-, and unglycosylated
forms of PrPSc was faintly detectable in samples exposed
to SPC-PL alone followed by PK (Figure 1, lane 3). Im-
munoreactivity was undetectable in samples treated with
SPC-PH alone followed by PK exposure, or either con-
centration of SPC-P combined with SDS and followed
by PK (Figure 1, lanes 4–6). Control samples exposed to
SDS alone, PK alone, or SDS followed by PK retained
PrP-immunoreactivity (Figure 1A and B, lanes 7–9).
Mouse bioassay
Residual infectivity in treated samples was assayed via
intracranial inoculation of tga20 mice. The average num-
ber of days to terminal disease for the positive control
group (untreated RML-positive brain homogenate) was
65.5 ± 3.4 days, which is typical of RML disease kinetics
in tga20 mice inoculated intracranially [30]. As previ-
ously reported [29], ten-fold serial dilutions of this stock
resulted in increased mean incubation times and survival
percentages (Table 1). The survival curves generated
from these data were used as the comparative standard
when evaluating survival time in mice inoculated with
treated samples and for approximating reductions in in-
fectivity. Consistent clinical signs observed in scrapie-
affected mice included ataxia that progressed to a listing
or rolling gait in some cases, pelvic limb paresis, and
lethargy. All but 2 animals in the negative control group
(treated RML-negative brain homogenate) survived until
study termination. One mouse was euthanized due to se-
vere hydrocephalus and the cause of death of the other
mouse was undetermined.
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Mice inoculated with samples exposed to SPC-PL or
SDS-PH alone followed by PK had mean incubation
times of 107 ± 39 and 98 ± 16.8 days, respectively, corre-
sponding to an approximate 2–3 log10 reduction in in-
fectivity (Figure 2). Two of 19 mice (11%) in the SPC-PL
group survived until study termination, while all mice in
the SDS-PH group were euthanized due to severe clinical
signs of scrapie. Exposure to the combination of SPC-P
and SDS followed by PK resulted in a 4–5 log10 reduc-
tion in infectivity (Figure 2). The mean incubation time
for this combination using SPC-PL was 431 ± 72.4 days,
with 73% of mice surviving until study termination. Two
mice from this group were censored from survival statis-
tics due to intercurrent disease. For the combination
using SPC-PH, only 1 mouse developed clinical signs at
108 days post-inoculation and was definitively diagnosed
with scrapie (88% survival). Four mice in this group died
within 7 days of inoculation due to complications from
the procedure, and 4 additional mice were later censored
due to intercurrent disease. Mice inoculated with sam-
ples exposed to PK alone had an average incubation
time of 62 ± 5.2 days with 0% survival. Mice inocu-
lated with samples exposed to SDS alone followed by
PK had a mean incubation time of 86 ± 7.1 days,
corresponding to an approximate 2 log10 reduction in
infectivity but 0% survival.
Discussion
Oxidizing agents have been used with variable success in
prion inactivation studies. Recent studies applying vapor-
ized hydrogen peroxide (VHP) to prion-contaminated
stainless steel surfaces have demonstrated significant re-
ductions in infectivity for hamster-adapted scrapie and
mouse-adapted BSE strains [25,28]. A 4.5-5.6 log10 reduc-
tion in infectivity of the hamster-adapted 263 K scrapie
agent was demonstrated after treatment of contaminated
steel wires with VHP alone or in combination with an en-
zymatic cleaner [28]. Similarly, exposure of wires contami-
nated with the mouse-adapted 6 PB1 strain of BSE to
VHP alone resulted in a reduction of > 5.5 logs [25]. In
contrast, a ≤ 1 log10 reduction in infectivity was demon-
strated with liquid hydrogen peroxide [25]. Our prior
work examining SPC-P treatment alone also demon-
strated little to no (≤ 1 log10) reduction in infectivity of the
RML scrapie agent [29]. While VHP has demonstrated
greater efficacy against prions, we felt the efficacy of liquid
hydrogen peroxide might be improved in combination
with other protein-disrupting conditions and compounds,
Table 1 Average incubation times and survival
percentages of tga20 mice inoculated intracranially with
serially diluted or treated RML scrapie brain homogenate
Group Dilution or treatment Mean incubation time
in days ± SD (% survival)
RML titration series*
100 66 ± 3.4 (0%)
10-1 74 ± 3.3 (0%)
10-2 83 ± 6.1 (0%)
10-3 128 ± 29.1 (22%)
10-4 184 ± 39.6 (78%)
10-5 through 10-12 N/A (100%) – study termination
Treated RML
SPC-PL
* 67 ± 2.6 (0%)
SPC-PH
* 70 ± 6.0 (0%)
SPC-PL + SDS
* 93 ± 9.7 (0%)
SPC-PH + SDS
* 93 ± 7.6 (0%)
1 SPC-PL ∏ PK 107 ± 39.0 (11%)
2 SPC-PH ∏ PK 98 ± 16.8 (0%)
3 SPC-PL + SDS ∏ PK 431 ± 72.4 (73%)
4 SPC-PH + SDS ∏ PK 108
^ (88%)
5 SDS control 85 ± 12.3 (0%)
6 PK control 62 ± 5.2 (0%)
7 SDS ∏ PK control 86 ± 7.1 (0%)
*Smith et al. [29]; ^only 1 mouse in this group was euthanized due to
clinical scrapie.
SD standard deviation.
Figure 1 Western blot of PrP in treated brain homogenate from
RML scrapie-affected C57Bl/6 mice without (A) or with (B) PK
pretreatment prior to immunoblotting. PrP-immunoreactivity was
faintly detectable in samples exposed to SPC-PL alone followed by
PK (lane 3) and undetectable in samples treated with either SPC-PH
alone or with SPC-PL or SPC-PH combined with SDS followed by PK
(lanes 4–6). Control samples included untreated RML brain homogenate
(lane 2), SDS treatment only (lane 7), SDS followed by PK (lane 8), and PK
treatment only (lane 9). Additional exposure of samples to PK prior to
immunoblotting (as part of the WB protocol for PrPSc) did not result in
loss of PrPSc immunoreactivity in control samples. Lanes 1 and 10,
molecular weight marker. Abbreviations: MW, molecular weight.
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such as the alkaline conditions attained with SPC solution
and the denaturing and proteolytic effects of SDS and PK,
respectively.
In this report, we investigated the viability of combin-
ing sodium percarbonate, SDS, and PK to inactivate the
RML scrapie agent. Treated samples were evaluated for
PrPSc immunoreactivity by WB and residual infectivity
by mouse bioassay. Product choice and treatment condi-
tions for this study were defined based on our aforemen-
tioned study in which we demonstrated exposure of the
RML scrapie agent to SPC-P with or without SDS in-
creased the sensitivity of PrPSc to PK, but did not eliminate
infectivity. The results of the current study demonstrating
loss of PrPSc immunoreactivity after treatment with SPC-
PH alone, or either concentration of SPC-P combined with
SDS, followed by PK are in agreement with previous find-
ings. Exposure of brain homogenate to this combination
resulted in a > 4 log10 reduction in infectivity, with 73% of
challenged mice from the SPC-PL + SDS→ PK group and
88% of mice from the SPC-PH + SDS→ PK group surviv-
ing until study termination. Treatment with PK alone had
no effect on infectivity, while treatment with SDS alone or
SDS→ PK resulted in an approximate 2 log10 reduction,
but 0% survival. Treatment with either SPC-PL or SPC-PH
alone followed by PK also had a modest impact on infect-
ivity resulting in a 2–3 log10 reduction in infectivity, but
with 11% and 0% survival, respectively. In our previous
study we reported that SPC-PL or SPC-PH alone had little
to no effect on infectivity (≤ 1 log10), but in combination
with SDS resulted in a 2–3 log10 reduction in infectivity
but with few survivors. Taken together, these data indicate
the most viable approach is utilizing all components in
combination.
Both concentrations of SPC-P used in this study gen-
erated a pH of approximately 11 in solution. We previ-
ously evaluated the effect of pH on this particular
inoculum and demonstrated loss of PrPSc immunoreac-
tivity after incubation of brain samples buffered with
0.35 M Na2HPO4 (pH 11.0). It is well established that
prion infectivity is reduced under extremely basic condi-
tions, such as exposure to NaOH (pH 12–14) [31-33].
While the pH generated by SPC-P is lower at near 11, it
appears to be a favorable characteristic of the compound
with regard to PrPSc protease sensitivity and is likely
contributing to the mechanism of infectivity reduction
observed in this study. Also, although treatment with
this combination rendered PrPSc sensitive to PK and
substantially decreased infectivity, it did not completely
eliminate infectivity. This was not unexpected, as a num-
ber of studies have demonstrated dissociation of PrPSc
and infectivity [2,5,34,35]. Our results support the
conclusion that biochemical analysis alone is insuffi-
cient for determination of prion infectivity. The ob-
served PrPSc/infectivity mismatch warrants a number
of considerations including WB sensitivity, epitope
disruption by inactivation treatments, and alternative
infectious agents to solely PrPSc. It is possible the amount
of residual PrPSc in our treated samples was below the
detection limit of our WB, or it may be that a true dissoci-
ation of PrPSc and TSE infectivity exists supporting the
actuality of alternative infectious agents to PrPSc [36]. A
recent study has demonstrated poor correlation between
infectivity and WB results for sheep scrapie and sheep
BSE [35], in line with observations that PK-sensitive PrP
particles are associated with disease [2,37].
Conclusions
This study is the first to report the efficacy of a novel
combination of oxidizing agent, detergent, and protease
to inactivate prions. Exposure of the RML scrapie agent
to an SPC-containing product combined with SDS
followed by PK exposure substantially reduced prion
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Figure 2 Effect of various treatment conditions on scrapie infectivity in tga20 mice. Kaplan-Meier survival curves were generated to
compare treatment conditions to 10-fold serial dilutions of RML scrapie in tga20 mice. Treatment with PK alone had no effect on infectivity.
Treatment with SDS alone or SDS followed by PK (SDS→ PK) yielded an approximate 2 log10 reduction in infectivity with 0% survival. Similarly,
treatment with either SPC-PL or SPC-PH alone followed by exposure to PK resulted in a 2–3 log10 reduction in infectivity. The combination of
SPC-PL or SPC-PH with SDS followed by PK resulted in a 4–5 log10 reduction in infectivity with 73% and 88% survival, respectively. Abbreviations:
SPC-PL or H, low or high concentration sodium percarbonate-based product; SDS, sodium dodecyl sulfate; PK, proteinase K.
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infectivity by 4–5 logs. While this combination did not
completely eliminate infectivity, it is feasible that further
investigation and protocol modification may result in
improved efficacy yielding a non-hazardous and widely
applicable solution for prion decontamination.
Methods
Inactivation of inoculum
Brain samples from negative control or RML-positive
mice were prepared as 10% w/v brain homogenates in
phosphate buffered saline as described previously [29].
Homogenates were diluted to a concentration of 5% in
either a 2.1% (SPC-PL, pH 10.7) or 21.0% (SPC-PH,
pH 10.6) solution of a commercial product containing
SPC (OxiMagic™, Clorox Company; 50-60% SPC) with
or without 2.5% sodium dodecyl sulfate (SDS). Manufac-
turer’s instructions on concentration were followed
(2.1% working solution), but additional parameters were
experimentally defined. Samples were agitated under
ambient oxygen in microcentrifuge tubes at 25°C for
30 min. Next, proteinase K (PK) (USB Corporation) was
added to a final concentration of 0.08 mg/mL and
samples were incubated at 48°C for 40 min. Pefabloc
(Roche) was added to a final concentration of 1 mg/mL
to quench PK activity. Samples were then diluted with
sterile saline to a final concentration of 1% for inocula-
tion (final pH values of 10.3 and 10.6 for SPC-PL and
SPC-PH-treated samples, respectively). Samples were in-
oculated intracranially (see below) into 10–20 tga20 mice
per treatment condition. Mice (n = 10/group) inoculated
with RML-positive brain homogenate exposed to
0.08 mg/mL PK alone at 48°C for 40 min, or 2.5% w/v
SDS alone or followed by PK (as above) were included
as PK-only, SDS-only, and SDS PK controls, respect-
ively. Mice (n = 10/group) inoculated with RML-negative
brain homogenate treated with SPC-P with or without
SDS served as negative controls. Samples were stored
at −20°C until thawing for western blot analysis and
inoculation into tga20 mice. Mice were inoculated
(see below) within 12–24 hours of sample treatment.
Western blotting
Treated samples from each inactivation condition along
with controls were examined for PrPSc via western blot.
Pretreatment of brain homogenate with PK was
performed on one set of blots and omitted on repeated
blotting of the same samples. Briefly, samples were
digested with PK using a final concentration of
0.08 mg/mL of at 48°C for 40 min. Pefabloc was
added to a final concentration of 0.1 mg/mL to quench
PK activity. Samples were dissolved in SDS-PAGE sample
buffer and analyzed by standard western blotting proce-
dures. A tissue equivalent of 1.0 mg was loaded onto the
gel for each sample. PrPSc was detected using monoclonal
antibody 6H4 (Prionics, La Vista, NE) at a 1:10,000
(0.1 μg/mL) dilution applied for 1 hr at room temperature
or 4°C overnight. A biotinylated sheep anti-mouse second-
ary antibody and a streptavidin-horseradish peroxidase
(HRP) conjugate (GE Healthcare, Pittsburgh, PA) were
used in conjunction with the ECL Plus detection kit
(GE Healthcare) to detect immunolabeling. Secondary
antibody and streptavidin-HRP conjugate incubations
were conducted at room temperature for 1 hour. Blots
were developed using the Typhoon 9410 Variable Mode
Imager (Molecular Dynamics, Sunnyvale, CA).
Mouse bioassay
Comparative survival curves were generated as previously
described [29] in mice of the B6;129S7-Prnptm1CweTg
(Prnp)a20Cwe/CweCnrm (tga20) line [30]. For all inocula-
tions, tga20 mice were anesthetized with isoflurane and a
30 gauge tuberculin syringe was used to inject 20 microli-
ters of brain homogenate into the right cerebral hemi-
sphere at a depth of 3–5 mm. Mice were monitored for
48 hours post-inoculation for procedure-related adverse
events. Mice were then monitored daily and euthanized
when they displayed unequivocal neurological signs, or at
the time of study termination (560 days post-inoculation).
Scrapie diagnosis was confirmed with a combination of
WB, histopathology, and immunohistochemistry for PrP.
Experimental and control groups included mice inocu-
lated with RML brain homogenate treated as follows: 1)
SPC-PL followed by PK, 2) SPC-PH followed by PK, 3)
SPC-PL + SDS followed by PK, 4) SPC-PH + SDS followed
by PK, 5) SDS only at 25°C x 30 min, 6) PK only at
48°C for 40 min, 7) SDS followed by PK (Table 1). This
experiment was carried out in accordance with the Guide
for the Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources, National Academy of
Sciences, Washington, DC) and was approved by the
National Animal Disease Center’s Animal Care and Use
Committee (protocol #2422).
Statistics
Kaplan-Meier survival curves were generated using stat-
istical software (Prism version 4.0, GraphPad Software).
To estimate reductions in infectivity, survival curves
from treated groups were compared to those of the titra-
tion study using the logrank test with a level of statistical
significance of 0.05. Mice that died within the first
21 days PI due to complications related to intracranial
inoculation or were removed from the study for humane
reasons (e.g. intercurrent disease, injuries) prior to devel-
oping clinical signs were censored and not included in
survival analyses.
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